Results 11 to 20 of about 4,766 (189)

Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir [PDF]

Clinical Infectious Diseases, 2021
Abstract Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association.
Kirkegaard-Klitbo, Ditte Marie, Thomsen, Magda Teresa, Gelpi, Marco, Bendtsen, Flemming, Nielsen, Susanne Dam, Benfield, Thomas   +5 more
openaire   +4 more sources

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

HIV/AIDS: Research and Palliative Care, 2012
Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31Médecins Sans Frontières, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease
Lee JSF, Calmy A, Andrieux-Meyer I, Ford N   +3 more
doaj   +4 more sources

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV [PDF]

AIDS, 2018
To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.Nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and their children in the United States.Intensive steady-state
Momper, Jeremiah D, Best, Brookie M, Wang, Jiajia, Capparelli, Edmund V, Stek, Alice, Barr, Emily, Badell, Martina L, Acosta, Edward P, Purswani, Murli, Smith, Elizabeth, Chakhtoura, Nahida, Park, Kyunghun, Burchett, Sandra, Shapiro, David E, Mirochnick, Mark   +14 more
openaire   +5 more sources

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +2 more sources

Supplementary Table from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m⁶A Methyltransferase METTL3

, 2022
Supplementary Table from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase ...
Zi-Jia Huang (14956611), Guo-Geng Zhang (14956608), Bin Li (14956623), Long Liao (810208), Wei Yu (43094), Shu-Jun Li (9335526), Yan He (116705), Jing Yang (13969), Qing-Yu He (14956617), Can-Can Zheng (14956614), Yan Li (14956620)   +10 more
core   +8 more sources

Supplementary Figure from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m⁶A Methyltransferase METTL3

, 2022
Supplementary Figure from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase ...
Zi-Jia Huang (14956611), Guo-Geng Zhang (14956608), Bin Li (14956623), Long Liao (810208), Wei Yu (43094), Shu-Jun Li (9335526), Yan He (116705), Jing Yang (13969), Qing-Yu He (14956617), Can-Can Zheng (14956614), Yan Li (14956620)   +10 more
core   +8 more sources

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

Frontiers in Cellular and Infection Microbiology, 2023
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos, Maria Casadellà, Marc Noguera-Julian, Rafael Micán-Rivera, Pere Domingo, Antonio Antela, Joaquin Portilla, Jesús Sanz, Marta Montero-Alonso, Jordi Navarro, Mar Masiá, Mar Masiá, Nieves Valcarce-Pardeiro, Antonio Ocampo, Laura Pérez-Martínez, Coral García-Vallecillos, María Jesús Vivancos, María Jesús Vivancos, Arkaitz Imaz, José Antonio Iribarren, José Hernández-Quero, Judit Villar-García, Pilar Barrufet, Roger Paredes, Roger Paredes, INSTINCT study group, Mariona Perera, Anna Chamorro, Cristina Miranda, Nástor Sánchez, Anna Garcı́á, Núria Pérez, Juan González Garcı́á, María del Mar Gutiérrez, María Gracia Mateo, Elena Losada, Sergio Reus, Vicente Boix, Diego Torrús, Esperanza Merino, Angela Gutiérrez Liarte, Adrià Curran, Félix Gutiérrez, Anna Mariño Callejo, Alvarez Diaz Hortensia, Antonio Ocampo Hermida, Celia Miralles, Laura Labajo Leal, Guillermo Pousada, José Ramon Blanco, José Antonio Oteo, Ibarra Valvanera, Mercedes Sanz, Luis Metola, Juan Pascua, Daniel Podzamczer, Camila Piatti, Maialen Ibarguren, Laia Arbones, Marta Ruiz, Sara Cervanntes, Helena Pera, Jessica Toro, Nuria Perez-Alvarez, Anna Garcia   +64 more
doaj   +1 more source

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia

Viruses, 2020
Even with an efficient combination of antiretroviral therapy (ART), which significantly decreases viral load in human immunodeficiency virus type 1 (HIV-1)-positive individuals, the occurrence of HIV-1-associated neurocognitive disorders (HAND) still ...
Yuqing Gong, Kaining Zhi, Prashanth K. B. Nagesh, Namita Sinha, Pallabita Chowdhury, Hao Chen, Santhi Gorantla, Murali M. Yallapu, Santosh Kumar   +8 more
doaj   +1 more source

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundNew multi-purpose prevention technology (MPT) products are needed to prevent human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV2).
Andrea R. Thurman, Louise A. Ouattara, Nazita Yousefieh, Peter L. Anderson, Lane R. Bushman, Xi Fang, Homaira Hanif, Meredith Clark, Onkar Singh, Gustavo F. Doncel   +9 more
doaj   +1 more source

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source